永安药业(002365) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥838,814,941.70, a decrease of 13.78% compared to ¥972,890,144.84 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥61,766,022.21, a significant increase of 601.65% from a loss of ¥12,312,563.51 in 2023[6]. - The cash flow from operating activities for 2024 was ¥105,712,681.54, down 52.21% from ¥221,196,161.28 in 2023[6]. - The basic earnings per share for 2024 was ¥0.2107, compared to a loss of ¥0.0418 in 2023, marking a 604.07% increase[6]. - The total assets at the end of 2024 were ¥2,308,602,905.85, a decrease of 1.64% from ¥2,347,138,093.66 at the end of 2023[6]. - The net assets attributable to shareholders at the end of 2024 were ¥1,993,780,889.08, reflecting a slight increase of 0.50% from ¥1,983,913,143.72 at the end of 2023[6]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥26,758,071.75 in 2024, up 135.21% from a loss of ¥75,995,354.37 in 2023[6]. - The company achieved total revenue of ¥838,814,941.70 in 2024, a decrease of 13.78% compared to ¥972,890,144.84 in 2023[48]. - The revenue from the pharmaceutical manufacturing sector was ¥634,731,166.80, accounting for 75.67% of total revenue, down 4.14% from ¥662,169,543.45 in the previous year[48]. - The health food segment generated ¥103,757,455.44, representing 12.37% of total revenue, which is a decline of 33.81% from ¥156,767,499.19 in 2023[48]. Shareholder Information - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total share capital of 289,145,150 shares after repurchase[5]. - The company has repurchased a total of 5,537,350 shares as of the disclosure date[5]. - The total cash dividend amount, including other methods, is 53,084,713.50 yuan, which accounts for 100% of the total profit distribution[136]. - The company reported a positive profit available for distribution of 837,228,722.92 yuan[136]. - After share buybacks, the final cash dividend distribution will be based on 292,821,450 shares, resulting in an actual total cash distribution of ¥29,282,145.00[134]. Product Development and Market Position - The company has expanded its product offerings to include epoxy ethane and special dietary foods, such as creatine[16]. - The company introduced a new business line in special dietary foods (creatine) through independent research and development during the reporting period[27]. - The company has developed a new product, monohydrate creatine, leveraging existing production and sales channels, aiming to reverse losses from previous operations[32]. - The company has developed over 180 new products in functional nutrition, health food, and special dietary food categories during the reporting period[41]. - The company is the largest taurine production base globally, with an annual production capacity of 58,000 tons, accounting for approximately 50% of the market share[29]. Research and Development - The company holds 50 patents related to taurine production technology, showcasing its strong R&D capabilities and experience in the field[34]. - The company has obtained 7 new patents during the reporting period, including 2 invention patents related to taurine production[40]. - The company has established a technology platform for probiotic products, incorporating innovative three-layer crystal ball technology to enhance the viability and stability of probiotics, thereby increasing market competitiveness[62]. - The number of R&D personnel increased to 172 in 2024, reflecting a growth of 2.38% compared to 168 in 2023, although the proportion of R&D personnel decreased slightly from 18.94% to 18.49%[62]. - R&D expenditure decreased by 10.91% to ¥36,974,497.81, while the proportion of R&D expenditure to operating revenue increased to 4.41% from 4.27%[63]. Risk Management - The company acknowledges various risks, including safety, operational, exchange rate, and management risks[5]. - The company has identified five major hazard sources and is implementing strict safety management measures to mitigate risks[88]. - The company faces operational risks due to rising fixed costs and intense competition in the taurine market, particularly from international trade uncertainties[88]. - The company is exposed to exchange rate risks as a significant portion of its revenue is denominated in USD, which may lead to substantial foreign exchange losses[88]. Governance and Compliance - The company is committed to enhancing its governance structure and compliance with legal regulations to protect shareholder rights[94]. - The company has established a complete and independent business system, including production, supply, and sales systems, ensuring operational independence from the controlling shareholder[99]. - The board of directors consists of 6 members, including 3 independent directors, ensuring compliance with legal requirements and effective governance[96]. - The company maintains strict information disclosure practices, ensuring timely and accurate communication with all shareholders[98]. - The company has established an independent financial accounting system and management procedures, ensuring financial independence from the controlling shareholder[100]. Environmental Responsibility - The company has invested approximately 2.1222 million yuan in wastewater management and about 206,500 yuan in environmental protection tax for the year 2024[152]. - The company has implemented a clean production audit and prioritized the use of clean energy to reduce carbon emissions, ensuring a steady decrease in emissions without increasing production capacity[153]. - The company has maintained a zero environmental accident record in 2024, continuously investing in environmental protection and management efforts[162]. - Yong'an Pharmaceutical's wastewater treatment facilities operate normally, utilizing activated sludge nitrogen removal technology to meet discharge standards[149]. Employee Management - The total number of employees at the end of the reporting period is 930, with 612 from the parent company and 318 from major subsidiaries[129]. - The total employee compensation during the reporting period accounted for 5.56% of the company's total costs, with core technical personnel making up 20.54% of the workforce and receiving 27.94% of total compensation[130]. - The company has achieved a 100% occupational disease examination rate for employees, ensuring that all relevant personnel undergo pre-employment, in-service, and exit health checks[161]. - The company has established a comprehensive labor management system to protect employees' legal rights and provide a good working environment[158]. Legal Matters - The company is facing a patent infringement lawsuit in the U.S. with a claim amount of 0 million RMB, and it has not yet been executed[183]. - The company is involved in multiple lawsuits, with a total of 8 cases reported, and has won all of them, with a total amount involved of 12.68 million yuan[184]. - The company has successfully recovered 1.92 million yuan in a settlement agreement related to a commercial dispute, with remaining amounts still pending[185]. - The company has engaged in several legal actions to recover debts, with amounts involved ranging from 6.65 million yuan to 121.55 million yuan across different cases[186].